New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

Building on the recent approval of Johnson & Johnson's TECVAYLI® plus DARZALEX FASPRO®, MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI® as early as second line TECVAYLI® delivered deep and durable responses with nearly two-thirds of patients...